C.J. Lintott

777 total citations
19 papers, 249 citations indexed

About

C.J. Lintott is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, C.J. Lintott has authored 19 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Molecular Biology. Recurrent topics in C.J. Lintott's work include Lipoproteins and Cardiovascular Health (8 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and BRCA gene mutations in cancer (3 papers). C.J. Lintott is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and BRCA gene mutations in cancer (3 papers). C.J. Lintott collaborates with scholars based in New Zealand, Australia and Japan. C.J. Lintott's co-authors include Russell Scott, Peter M. George, Brett Shand, Jon Bremer, W. H. F. Sutherland, K. M. Bowen, Paul Zimmet, Lesley V. Campbell, Timothy A. Welborn and M. C. Robertson and has published in prestigious journals such as The American Journal of Cardiology, Atherosclerosis and Journal of Medical Genetics.

In The Last Decade

C.J. Lintott

18 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.J. Lintott New Zealand 10 130 82 55 38 37 19 249
Delia Silverio United States 9 123 0.9× 82 1.0× 81 1.5× 59 1.6× 34 0.9× 10 301
Nuntakorn Thongtang Thailand 9 188 1.4× 137 1.7× 41 0.7× 45 1.2× 40 1.1× 34 310
Jane Wilkinson United Kingdom 13 156 1.2× 148 1.8× 149 2.7× 57 1.5× 17 0.5× 21 509
Lukáš Zlatohlávek Czechia 11 108 0.8× 50 0.6× 65 1.2× 30 0.8× 15 0.4× 29 293
Simone Sorkin Arazi Brazil 10 163 1.3× 63 0.8× 59 1.1× 16 0.4× 27 0.7× 15 282
Heta Aleksandra Gylling Finland 6 220 1.7× 67 0.8× 55 1.0× 20 0.5× 32 0.9× 11 329
Aled Roberts United Kingdom 8 88 0.7× 67 0.8× 96 1.7× 70 1.8× 9 0.2× 11 317
Anna Laura Cremonini Italy 9 86 0.7× 36 0.4× 65 1.2× 29 0.8× 13 0.4× 15 282
Olivier Scruel France 11 142 1.1× 141 1.7× 82 1.5× 23 0.6× 8 0.2× 20 311
Pablo Corral Argentina 8 154 1.2× 93 1.1× 52 0.9× 69 1.8× 22 0.6× 42 272

Countries citing papers authored by C.J. Lintott

Since Specialization
Citations

This map shows the geographic impact of C.J. Lintott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J. Lintott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J. Lintott more than expected).

Fields of papers citing papers by C.J. Lintott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J. Lintott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J. Lintott. The network helps show where C.J. Lintott may publish in the future.

Co-authorship network of co-authors of C.J. Lintott

This figure shows the co-authorship network connecting the top 25 collaborators of C.J. Lintott. A scholar is included among the top collaborators of C.J. Lintott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.J. Lintott. C.J. Lintott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lintott, C.J., et al.. (2021). Novel Presenilin-1 Mutation (Ala275Ser) Associated With Clinical Features of Dementia With Lewy Bodies. Alzheimer Disease & Associated Disorders. 35(4). 350–352. 2 indexed citations
2.
Lattimore, Vanessa, Michael T. Parsons, Amanda B. Spurdle, et al.. (2020). Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients. Breast Cancer Research and Treatment. 185(3). 583–590.
3.
Tan, Ai Ling, Carrie Innes, Amanda Tristram, et al.. (2019). Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand.. PubMed. 132(1490). 26–35. 1 indexed citations
4.
Gardner, R. J McKinlay, Ian Crozier, Donald R. Love, et al.. (2018). Penetrance and expressivity of the R858H CACNA1C variant in a five‐generation pedigree segregating an arrhythmogenic channelopathy. Molecular Genetics & Genomic Medicine. 7(1). e00476–e00476. 9 indexed citations
5.
Currie, Margaret J., et al.. (2015). Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing.. PubMed. 128(1419). 56–61. 6 indexed citations
6.
Lintott, C.J., et al.. (2002). Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Human Mutation. 19(3). 311–311. 35 indexed citations
7.
Scott, Russell, C.J. Lintott, Paul Zimmet, et al.. (1999). Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?. Diabetes Research and Clinical Practice. 43(3). 179–185. 26 indexed citations
8.
Lintott, C.J., et al.. (1995). Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency. The American Journal of Cardiology. 76(1-2). 97A–101A. 27 indexed citations
9.
Kotze, Maritha J., E. Langenhoven, Odell Loubser, et al.. (1995). Screening for mutations in exon 4 of the LDL receptor gene: identification of a new deletion mutation.. Journal of Medical Genetics. 32(5). 379–382. 11 indexed citations
10.
Scott, Russell, et al.. (1994). Dexfenfluramine reduces cardiovascular risk factors.. PubMed. 18(4). 199–205. 16 indexed citations
11.
Lintott, C.J., et al.. (1993). Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Australian and New Zealand Journal of Medicine. 23(4). 381–386. 15 indexed citations
12.
Lintott, C.J., et al.. (1993). Lipid, lipoprotein and apolipoprotein distributions in an elderly New Zealand population. Australian and New Zealand Journal of Medicine. 23(2). 162–167. 3 indexed citations
13.
Lintott, C.J., Carl Hanger, Russell Scott, R Sainsbury, & C. Frampton. (1992). Prevalence of diabetes mellitus in an ambulant elderly New Zealand population. Diabetes Research and Clinical Practice. 16(2). 131–136. 6 indexed citations
14.
Lintott, C.J. & Russell Scott. (1992). HMG-CoA Reductase Inhibitor Use in the Aged. Drugs & Aging. 2(6). 518–529. 7 indexed citations
15.
Bremer, Jon, Russell Scott, & C.J. Lintott. (1991). Oat bran and cholesterol reduction: evidence against specific effect. Australian and New Zealand Journal of Medicine. 21(4). 422–426. 19 indexed citations
16.
Scott, Russell, et al.. (1991). Simvastatin and side effects.. PubMed. 104(924). 493–5. 36 indexed citations
17.
Lintott, C.J., Russell Scott, Edwin R. Nye, M. C. Robertson, & W. H. F. Sutherland. (1989). SIMVASTATIN (MK 733): AN EFFECTIVE TREATMENT FOR HYPERCHOLESTEROLEMIA. Australian and New Zealand Journal of Medicine. 19(4). 317–320. 14 indexed citations
18.
Lintott, C.J., Russell Scott, & Jon Bremer. (1989). Treatment of hyperlipidaemia with acipimox. Current Medical Research and Opinion. 11(6). 374–379. 3 indexed citations
19.
Janus, Edward, et al.. (1985). Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis. 57(2-3). 249–266. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delia Silverio Breakdown of academic impact, for papers by Nuntakorn Thongtang Breakdown of academic impact, for papers by Jane Wilkinson Breakdown of academic impact, for papers by Lukáš Zlatohlávek Breakdown of academic impact, for papers by Simone Sorkin Arazi Breakdown of academic impact, for papers by Heta Aleksandra Gylling Breakdown of academic impact, for papers by Aled Roberts Breakdown of academic impact, for papers by Anna Laura Cremonini Breakdown of academic impact, for papers by Olivier Scruel Breakdown of academic impact, for papers by Pablo Corral
Rankless by CCL
2026